2.4.1.155: alpha-1,6-mannosyl-glycoprotein 6-beta-N-acetylglucosaminyltransferase
This is an abbreviated version!
For detailed information about alpha-1,6-mannosyl-glycoprotein 6-beta-N-acetylglucosaminyltransferase, go to the full flat file.
Word Map on EC 2.4.1.155
-
2.4.1.155
-
n-glycans
-
metastasis
-
oligosaccharide
-
n-linked
-
glycosyltransferases
-
n-glycosylation
-
lectin
-
udp-glcnac
-
asparagine-linked
-
trisaccharide
-
bisect
-
medicine
-
beta1,6-branched
-
gnt-ivs
-
complex-type
-
fucosyltransferase
-
polylactosamine
-
o-mannosylated
-
tetra-antennary
-
swainsonine
-
leukoagglutinating
-
glycomic
-
glcnac-t
-
diagnostics
-
drug development
-
pharmacology
-
biotechnology
- 2.4.1.155
- n-glycans
- metastasis
- oligosaccharide
-
n-linked
- glycosyltransferases
-
n-glycosylation
- lectin
- udp-glcnac
-
asparagine-linked
- trisaccharide
-
bisect
- medicine
-
beta1,6-branched
- gnt-ivs
-
complex-type
-
fucosyltransferase
-
polylactosamine
-
o-mannosylated
-
tetra-antennary
- swainsonine
-
leukoagglutinating
-
glycomic
-
glcnac-t
- diagnostics
- drug development
- pharmacology
- biotechnology
Reaction
Synonyms
acetylglucosaminyltransferase, uridine diphosphoacetylglucosamine-alpha-mannoside beta1-6-UDP-N-acetylglucosamine:alpha-mannoside-beta1,6 N-acetylglucosaminyltransferase, alpha-1,3(6)-mannosylglycoprotein beta-1,6-N-acetylglucosaminyltransferase, alpha-1,6-mannosyl-glycoprotein 6-beta-N-acetylglucosaminyltransferase, alpha-mannoside beta-1,6-N-acetylglucosaminyltransferase, beta N-acetylglucosaminyltransferase V, beta-1,6-N-acetylglucosaminyltransferase V, beta1, 6-N-acetylglucosaminyltransferase V, beta1,6-N-acetylglucosaminyltransferase, beta1,6-N-acetylglucosaminyltransferase V, beta1,6-N-acetylglucosaminyltransferase-V, Glc-NAcT-V, GlcNAcT-V, GlcNAcTase-V, glycosyltransferase, GnT-IV, GnT-IX, GnT-V, GnT-Va, GnT-VB, Golgi beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase V, Golgi UCD-GlcNAc:N-acetylglucosaminyltransferase 5, mannoside acetylglucosaminyltransferase 5, Mgat5, N-acetylglucosaminyltransferase V, N-acetylglucosaminyltransferase Va, N-acetylglucosaminyltransferase-V, N-acetylglucosaminyltransferase-Va, N-acetylglucosaminyltransferase-Vb, N-acetylglucsaminyltransferase V, UDP-N-acetylglucosamine:a-mannoside beta-1,6-N-acetylglucosaminyltransferase
ECTree
2.4.1.155 alpha-1,6-mannosyl-glycoprotein 6-beta-N-acetylglucosaminyltransferaseAdvanced search results
results (
results (Application
Application on EC 2.4.1.155 - alpha-1,6-mannosyl-glycoprotein 6-beta-N-acetylglucosaminyltransferase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
APPLICATION 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
biotechnology
-
transfection of sense cDNA of enzyme results in increase in the N-acetylglucosamine-beta1,6-mannose-alpha1,3-branch of epidermal growth factor receptor. Transfection with antisense CDNA of enzyme rsults in reverse reaction. Altered expression of enzyme will change the glycan structure and function of epidermal growth factor receptor, which may modify downstream signal transduction
diagnostics
the enzyme is useful as diagnostic marker for gastric adenocarcinomas: low intratumoral MGAT5 density is associated with poor differentiation, N classification, TNM stage, and Kiel stage, and is an independent prognosticator for poor overall survival. The combination of intratumoral MGAT5 expression and TNM or Kiel staging systems has a better predictive power for overall survival. Applying the prognostic value of intratumoral MGAT5 density to TNM stage III+IV and Kiel stage IIIB+IV groups shows a better risk stratification for overall survival in patients with late-stage gastric cancer, overview
drug development
COS may serve as a potential therapeutic candidate for the treatment of metastatic breast cancer
medicine
pharmacology
-
the work is a step toward intriguing innovative therapeutic strategies for trials currently in consider with glycosyltransferase in neurodegenerative disorders
additional information
-
an elevation of enzyme Gnt-V activity leads to radiosensitivity and migration of small cell lung cancer cells by inducing epithelial-mesenchymal transition, EMT, thereby highlighting Gnt-V as a potential therapeutic target for the prevention of EMT-associated tumour radioresistance and migration
medicine
-
link between elevated expression of enzyme and malignant transformation, macrophage fusion hybrids with Cloudman S91 mouse melanoma cells are highly metastatic in vivo, motile in vitro and express macrophage-associated traits of increased enzyme activity, beta1,6-branching and polylactosamine content
medicine
-
a selective inhibitor for this GnT-V secretion, a gamma-secretase inhibitor, could provide a useful strategy for the inhibition of tumor angiogenesis and progression
medicine
-
higher expression of GnT-V is correlated with a favorable prognosis for neuroblastoma patients. GnT-V may cause these tumors to regress by increasing their susceptibility to apoptosis
medicine
-
prognosis of thyroid carcinoma after surgery is not correlated with the expression GnT-V because the levels of expression is quite low in anaplastic (undifferentiated) carcinomas
medicine
-
a simple glycoproteomic strategy to identify the glycoproteins from breast tissue that bind to the lectin L-phytohemagglutinin is developed
medicine
-
conditional expression of beta1,6GlcNAc-branched N-glycans in postnatal tissues promotes anabolic metabolism and tissue renewal by adapting cellular sensitivities to growth and arrest cues
medicine
-
GnT-III transfection into highly pigmented, highly metastatic macrophage-melanoma fusion hybrids resulted in the suppression of both melanogenesis and motility
medicine
-
GnT-V and beta1-6 branching N-linked oligosaccharide expressions are downregulated during carcinogenesis and progression of human testicular germ cell tumors, GnT-V may be a promising recurrence predictor for stage I non-seminomatous germ cell tumors
medicine
-
high GnT-V expression is correlated with impaired clinical outcome in endometrial cancer patients, GnT-V is an independent prognostic factor for progression-free survival
medicine
-
knowledge of the biological behavior of metalloproteinases and tissue inhibitor of metalloproteinases and the roles in various diseases have an eventual goal of therapeutic uses and clinical trials of anti-cancer agents
medicine
-
the study demonstrates the effect of down-regulating GnT-V on glucose uptake and provides a new mechanistic link between GnT-V and GLUT1, since ER stress may cause apoptosis of tumor cells, selective modulation of GLUT1 may be a useful pro-apoptotic strategy for liver or other cancers
medicine
-
GnT-V expression correlated with a poor prognosis in gastric cancer patients due to metastases
medicine
-
enzyme expression is positively related with malignancy in HCC. The enzyme is both a differentiation marker and a potential target for the treatment of hepatocellular carcinoma
medicine
-
the enzyme is a potential therapeutic target for vascular inflammatory conditions
medicine
radiotherapy combining GnT-V down-regulation and cetuximab decelerates tumor growth
